

NEW γ -LACTAM HOMOLOGS OF PENEMS

Jacqueline Marchand-Brynaert^a, Blandine Couplet^a, Georges Dive^b and Léon Ghosez^{a*}

^aLaboratoire de Chimie Organique de Synthèse, Université Catholique de Louvain
place Louis Pasteur 1, B - 1348 Louvain-la-Neuve, Belgium


^bCentre d'Ingénierie des Protéines, Université de Liège, Chimie B-6,
B - 4000 Sart-Tilman/Liège, Belgium

(Received 1 April 1993)

Abstract : 3-Ethylthiohomopenems **5a** and **5b** were prepared from α -amino- γ -butyrolactone. Compound **5a** showed weak antibacterial properties.

Introduction :


The antibacterial properties of β -lactam antibiotics result from their capacity of acylating the active serine residue of Penicillin Binding Proteins (PBPs)¹. This has been correlated with the chemical reactivity of the β -lactam ring². However, recently, much less reactive lactams such as that of naturally occurring lactivicin **1** or of synthetic pyrazolidinones **2** were shown to exhibit antibacterial activity (Scheme 1)³⁻⁶. Yet, the related γ -lactams **3** and **4** displayed only low levels of in vitro activity, even when electron withdrawing groups (EWGs) were introduced on the carbon-carbon double bond in order to enhance the reactivity of the γ -lactam function^{7,8}.



Scheme 1

Structural Design :

A theoretical model for the acylation step of the PBPs has recently been proposed. It stresses out the role of water molecules in a concerted process involving a proton shuttle⁹. In this model, the scissile amide bond of the inhibitor is reacted with the duplex molecule "methanol-water" mimicking the active serine residue. A six-membered transition state was considered (Scheme 2)¹⁰. Reactant's and transition-state's structures were fully optimized by ab initio calculation using the STO-3G minimal basis set. At the saddle point equilibrium geometry, an analytical frequencies calculation was carried out in order to analyze the components of the eigenvector associated to the negative eigenvalue of the Hessian matrix. For each molecule, this eigenvector described the reorganization of the six-membered transition-state in the concerted methanolysis reaction. This mechanistic model indeed predicts a low activation energy (E_A) for a β -lactam fused to a five-membered ring (Table I, entry a), as well as for an isoxazolidinone related to lactivicin (entry b). Pyrazolidinones (entries c and d) are predicted to be less reactive in this model. A bicyclic γ -lactam related to the penems (entry e) shows the highest activation energy. Interestingly, the presence of an *electron-withdrawing* group on the carbon-carbon double bond does not lower the activation barrier (entry f), but a slight decrease of this barrier is observed when *electron-donating* substituents are borne by the double bond (entries g and h). We thus decided to prepare two representatives of homopenems **5** (Scheme 1, $R^2 = \text{SEt}$) and evaluate their biological activity.











Synthesis :

The synthetic plan (Scheme 3) closely follows that we had earlier applied to the synthesis of the related 2-heterosubstituted penems^{11,12}.


α -Amino- γ -butyrolactone (\pm) **6** was transformed into the corresponding t-Boc derivative which was reacted with an excess of methyl glycinate to give **7**¹³.

Table 1: Calculated Activation Energies

	Structure	E _A (kcal/mole)		Structure	E _A (kcal/mole)
a		16.039	e		22.008
b		17.926	f		22.138
c		20.762	g		21.551
d		19.500	h		20.900

Swern oxidation yielded an aldehyde which spontaneously cyclized to form a 3 : 1 mixture of *cis* and *trans* 5-hydroxy-2-pyrrolidinone **8**¹⁴. Substitution of the hydroxyl group by a thiol group was easily effected with hydrogen sulfide in the presence of a catalytic amount of *p*-toluenesulfonic acid. Acylation of the resulting thiol (*cis* : *trans* mixture 1 : 3) with phenyl chlorothiocarbonate yielded a mixture of *cis* and *trans* dithiocarbonates **9** which could be separated by chromatography on silica gel (dichloromethane : ethylacetate 95 : 5; yields : *cis*, 13 %; *trans* 44 %). Each isomer or the mixture of isomers could be cyclized to the bicyclic γ -lactams **10** by treatment with lithium hexamethyldisilazide (yields 62-70 %)¹⁵. They could be readily converted into the corresponding homopenems **11** by alkylation with ethyl iodide in the presence of triethylamine. When the sequence (v-vii; Scheme 3) was performed on the *cis* : *trans* mixture of isomers, without separations at any stages, a 1 : 3 mixture of *cis* and *trans* homopenems **11** was obtained.

A sample of each isomer was isolated by chromatography on silica gel (dichloromethane : ethylacetate 90 : 10) and characterized without ambiguity.




(i) $(\text{tBoc})_2\text{O}$, Et_3N , CH_2Cl_2 , 75%; (ii) $\text{Cl}^- \text{H}_3\text{N}^+ - \text{CH}_2\text{CO}_2\text{Me}$, Et_3N , 65°C , 74%; (iii) $(\text{COC})_2\text{O}$, DMSO , Et_3N , -70°C to 0°C , 74%; (iv) H_2S , $p\text{-TsOH cat.}$, CH_2Cl_2 , 0°C , 96%; (v) ClC(S)OPh , Et_3N , CH_2Cl_2 , 0°C , 57%; (vi) LiHMDS (4equiv.), THF , -15°C to 0°C , 62-70%; (vii) EtI , Et_3N , CH_2Cl_2 , 20°C , 73%; (viii) TFA , CH_2Cl_2 , 0°C , 100%; (ix) NEt_3 , R^1COCl , CH_2Cl_2 , 70-77%; (x) AlCl_3 , EtSH , CH_2Cl_2 , 20°C , 90% for **5a** and 75% for **5b**.

Scheme 3

Treatment of the mixture of isomers **11** with trifluoroacetic acid followed by acylation with the appropriate acid chloride in the presence of triethylamine yielded a *cis* : *trans* (~ 1 : 3) mixture of 7-acylamino-homopenems **12**¹⁶. The free acids **5a** and **5b** were obtained by treatment of the methyl esters with ethanethiol in the presence of aluminium trichloride¹⁷.

This synthetic scheme (Scheme 3) provides an easy access to homopenems of type **5** ($\text{R}^2 = \text{SR}$). The lack of stereoselectivity was not particularly harmful because the unwanted methyl esters **12 trans** could be readily equilibrated to give a mixture containing more than 82 % of the desired *cis* isomer (Scheme 4).



Biological studies :

Homopenems **5** cis and **5** trans were tested in vitro against representative gram-positive and gram-negative bacteria¹⁸. The cis : trans (1 : 4) mixture of **5a** showed weak antibacterial properties : MIC = 320 μ g/ml (*S. aureus*). This level of activity is in the range of that reported for other γ -lactams. At 100 μ M concentration, it also gave 15 % inhibition of the isolated D,D-carboxypeptidase from *Actinomadura* R39¹⁹. Neither **5a** nor **5b** were inhibitors of representative β -lactamases²⁰. Thus, the presence of a thioether group on the double bond of the homopenems does not improve the biological properties of the system.

Acknowledgments : This work was generously supported by the "Ministère de la Région Wallonne, Direction Générale des Technologies, de la Recherche et de l'Énergie" (convention MTLGG156/dos. 1810/07.10.91), the "Fonds National de la Recherche Scientifique" (Belgium) and SmithKline Beecham (Brockham Park, U.K.). We thank SmithKline Beecham for the biological evaluations.

References and notes :

1. "The Chemistry of Beta-Lactams"; Page, M.I. (Editor) Blackie Academic and Professional : London, 1992.
2. Woodward, R.B., in "The Chemistry of Penicillins" (Clarke, H.T.; Johnson, J.R.; eds) Princeton University Press : New Jersey, 1949, 440.
3. Nakao, Y. "Recent Advances in the Chemistry of β -Lactam Antibiotics" (Bentley, P.H.; Southgate, R.; eds), *Chem. Soc. Special Public.* **1989**, 70, 119.
4. Jungheim, L.N.; Barnett, C.J.; Gray, J.E.; Horcher, L.H.; Shepherd, T.A.; Sigmund, S.K. *Tetrahedron* **1988**, 44, 3119.
5. Indelicato, J.M.; Pasini, C.E. *J. Med. Chem.* **1988**, 31, 1227.
6. Jungheim, L.N.; Boyd, D.B.; Indelicato, J.M.; Pasini, C.E.; Preston, D.A.; Alborn Jr, W.E. *J. Med. Chem.* **1991**, 34, 1732.
7. Allen, N.E.; Boyd, D.B.; Campbell, J.B.; Deeter, J.B.; Elzey, T.K.; Foster, B.J.; Hatfield, L.D.; Hobbs, J.N.; Hornback, W.J.; Hunden, D.C.; Jones, N.D.; Kinnick, M.D.; Morin, J.M.; Munroe, J.E.; Swartzendruber, J.K.; Vogt, D.G. *Tetrahedron* **1989**, 45, 1905.
8. Hashiguchi, S.; Natsugari, H.; Ochiai, M. *J. Chem. Soc., Perkin I* **1988**, 2345.

9. Lamotte-Brasseur, J.; Dive, G.; Dideberg, O.; Charlier, P.; Frère, J.-M.; Ghuysen, J.-M. *Biochem J.* **1991**, *279*, 213.
10. Dive, G.; Peeters, D.; Leroy, G.; Guysen, J.-M. *J. Mol. Struct. THEOCHEM* **1984**, *107*, 117.
11. Ghosez, L.; Marchand-Brynaert, J.; Vekemans, J.; Bogdan, S. *Tetrahedron* **1983**, *39*, 2493.
12. Cossement, M.; Marchand-Brynaert, J.; Bogdan, S.; Ghosez, L. *Tetrahedron Lett.* **1983**, *24*, 2563.
13. Knobler, Y.; Bonni, E.; Sheradsky, T. *J. Org. Chem.* **1964**, *29*, 1229.
14. Barco, A.; Benetti, S.; Pollini, G.P. *Synthesis* **1979**, 68.
15. Methyl (5,7 *cis*)-1-aza-8-oxo-7-t-butoxycarbonylamino-4-thia-3-thioxo-bicyclo[3.3.0]octane-2-carboxylate **10**: IR (CH₂Cl₂) ν 1743, 1718 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃) δ 6.30 (ABX m, 1 J = 8.5 Hz, H-5), 5.51 (s, 1, H-2), 5.15-5.00 (m, 1, NH), 4.40-4.20 (m, 1, H-7), 3.83 (s, 3, OCH₃), 3.05-2.85 (m, 1, H-6), 2.80-2.65 (m, 1, H'-6), 1.48 (s, 9, tBu); ¹³C-NMR (50 MHz, CDCl₃) ppm 228.77 (C-3), 174.77 (C-8), 164.75 (CO ester), 156.00 (CO carbamate), 80.86 (CMe₃), 77.76 (C-2), 71.31 (C-5), 53.53 (OMe), 51.23 (C-7), 29.79 (C-6), 28.21 (tBu); Mass (FAB) m/e 347 (M+1)⁺, 291, 247, 231, 259, 225; Anal. C₁₃H₁₈N₂O₅S₂-calcd : %C, 45.07; %H, 5.24; %N, 8.09 - Found : %C, 44.82; %H, 5.30; %N, 8.07; mp 171°C; t.l.c. (SiO₂, EtOAc-CH₂Cl₂ 40:60) R_f = 0.44.
(5,7 *trans*) **10**: ¹H-NMR (200 MHz, CDCl₃) δ 6.11 (t, 1, J = 7 Hz, H-5), 5.55 (s, 1, H-2), 5.15 (br s, 1, NH), 4.65-4.50 (m, 1, H-7), 3.83 (s, 3, OCH₃), 3.50-3.25 (m, 1, H-6), 2.50-2.30 (m, 1, H'-6), 1.45 (s, 9, tBu); t.l.c. (SiO₂, EtOAc-CH₂Cl₂ 40:60) R_f = 0.30.
16. Methyl (5,7 *cis*)-1-aza-3-ethylthio-8-oxo-7-phenylacetamido-4-thia-bicyclo[3.3.0]oct-2-en-2-carboxylate **12a**: IR (CH₂Cl₂) ν 1730 (br), 1680 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃) δ 7.40-7.25 (m, 5, Ph), 6.30 (br d, 1, J = 5 Hz, NH), 5.80 (t, 1, J = 6.5 Hz, H-5), 4.81-4.68 (m, 1, H-7), 3.79 (s, 3, OCH₃), 3.62 (s, 2, CH₂-CONH), 3.40-3.25 (m, 1, H-6), 2.97-2.87 (ABX₃ m, 2, J = 7.4 Hz, S-CH₂-CH₃), 2.30-2.15 (m, 1, H'-6), 1.35 (ABX₃ m, 3, J = 7.4 Hz, S-CH₂-CH₃); ¹³C-NMR (50 MHz, CDCl₃) ppm 171.59 (C-8), 171.41 (CO amide), 159.58 (CO ester), 147.20 (C-3), 134.25, 128.81, 128.41, 127.22, 116.27 (C-2), 66.13 (C-5), 51.94 (OMe), 51.50 (C-7), 43.00 (PhCH₂), 35.84 (C-6), 29.82 (S-CH₂), 14.79 (S-CH₂-CH₃); Mass (FAB) m/e 393 (M+1)⁺, 361, 333, 305, 299, 289, 273; t.l.c. (SiO₂, EtOAc-CH₂Cl₂ 20:80) R_f = 0.20.
(5,7 *trans*) **12a**: ¹H-NMR (200 MHz, CDCl₃) δ 7.40-7.25 (m, 5, Ph), 6.40 (br d, 1, J = 6.4 Hz, NH), 5.86 (dd, 1, J = 7 and 1 Hz, H-5), 4.81-4.68 (m, 1, H-7), 3.80 (s, 3, OCH₃), 3.60 (s, 2, CH₂CONH), 3.04-2.85 (m, 1, H-6), 2.99-2.93 (ABX₃ m, 2, J = 7.4 Hz, S-CH₂-CH₃), 2.42-2.25 (ddd, 1, J = 17.8 and 7 Hz, H'-6), 1.36 (ABX₃ m, 3, J = 7.4 Hz, S-CH₂-CH₃); t.l.c. (SiO₂, EtOAc-CH₂Cl₂ 20:80) R_f = 0.32.
17. Node, M.; Nishide, K.; Sai, M.; Fujita, E. *Tetrahedron Lett.* **1978**, 5211.
18. Thrupp, L.D. in "Antibiotics in Laboratory Medicine" (Lorian, V.; ed), Williams and Wilkins, Baltimore, **1980**, pp 73-113.
19. Frère, J.M.; Joris, B. *Crit. Rev. Microbiol.*, **1985**, *11*, 299.
20. Thatcher, D.R. *Methods Enzymol.*, **1975**, *43*, 653; Ross, G.W. *Methods Enzymol.*, **1975**, *43*, 678.